pages_aktie_[isin]_directordealings_0
components_InsiderTable_9
Avacta Group
pages_aktie_[isin]_directordealings_2
pages_insiderkaeufe_[isin]__0 pages_insiderkaeufe_[isin]__1pages_insiderkaeufe_[isin]__2 pages_insiderkaeufe_[isin]__3pages_insiderkaeufe_[isin]__4 pages_insiderkaeufe_[isin]__5pages_aktie_[isin]_directordealings_3
Avacta Group PLC is a British company specializing in the development of innovative solutions for biotechnology and diagnostics. It was founded in 2004 by Eliot Forster and is headquartered in Wetherby, West Yorkshire. Avacta's history began with the development of Affimer technology, which offers an alternative to conventional antibodies. Affimers are synthetic peptides with high binding affinity to biological molecules, making them important tools for biomedical research and diagnostic applications. The company had limited resources in its early years, and it took several years to complete the development of Affimer technology. In recent years, Avacta has expanded its business model by offering licensed services to pharmaceutical companies. The company provides innovative screening methods and drug discovery tools based on Affimer technology. Avacta has partnerships with major companies such as LG Chem, Moderna, and Wockhardt. The partnership with LG Chem aims to use the platform technology for the development of Covid-19 therapeutics, while the collaboration with Wockhardt focuses on the creation of diagnostic kits and test systems. Avacta's main business areas are biotechnology and diagnostics. The biotechnology division offers screening services for pharmaceutical companies, with a focus on developing higher quality and more efficient antibodies using Affimers, which potentially provide better screening results than traditional antibodies. In the field of diagnostics, the company is working on the development of diagnostic test systems for disease diagnosis. Avacta has started developing diagnostic test kits for Covid-19 that can be used in a laboratory or at home. The company also has a partnership with Adeptrix, a diagnostic tool manufacturing company. Another important area of Avacta is therapeutic applications. Avacta's Affimer technology has already led to new clinical approaches in the development of cancer therapies. Avacta also has a pipeline program of Affimer therapeutics targeting various diseases, from cancer to inflammatory and neurodegenerative diseases. Avacta's products include licensed services for pharmaceutical companies, research kits for Affimer technology, and its own portfolio of Affimer products for various applications in research and diagnostics. The products are exported worldwide, and the company has offices in the United States and South Korea. Overall, Avacta Group PLC has become a major player in the biotechnology and diagnostics industry by expanding its Affimer technology to various applications. Partnerships with major pharmaceutical companies and the development of diagnostic test systems for Covid-19 have brought the company into the public eye and contribute to strengthening its position as a leading provider of Affimer technology in the industry.
components_InsiderFAQ__11
components_InsiderFAQ__0
components_InsiderFAQ__2
components_InsiderFAQ__4
components_InsiderFAQ__5
components_InsiderFAQ__7
components_InsiderFAQ__9
components_InsiderArticle__0
components_InsiderArticle__1
components_InsiderArticle__5
components_InsiderArticle__8
components_InsiderArticle__9
components_InsiderArticle__12
components_InsiderArticle__13
components_InsiderArticle__16
components_InsiderArticle__17
components_InsiderArticle__20
components_InsiderArticle__22
components_InsiderArticle__25
components_InsiderArticle__28
components_InsiderArticle__31
components_InsiderArticle__32
components_InsiderArticle__34
components_InsiderArticle__36
components_InsiderArticle__37
components_InsiderArticle__38
components_InsiderArticle__40
components_InsiderArticle__41 components_InsiderArticle__42 components_InsiderArticle__43 components_InsiderArticle__44 components_InsiderArticle__45
components_InsiderArticle__46
- components_InsiderArticle__48
- components_InsiderArticle__49
components_InsiderArticle__50
components_InsiderArticle__51
components_InsiderArticle__54
components_InsiderArticle__55
components_InsiderArticle__58
components_InsiderArticle__59
components_InsiderArticle__60
- components_InsiderArticle__61
- components_InsiderArticle__62
- components_InsiderArticle__63
- components_InsiderArticle__64
- components_InsiderArticle__65
- components_InsiderArticle__66
components_InsiderArticle__67
components_InsiderArticle__68
components_InsiderArticle__73
components_InsiderArticle__74
components_InsiderArticle__77
components_InsiderArticle__78
components_InsiderArticle__81
components_InsiderArticle__82
components_InsiderArticle__85
components_InsiderArticle__86 components_InsiderArticle__87. components_InsiderArticle__88
components_InsiderArticle__90
components_InsiderArticle__93
components_InsiderArticle__94
components_InsiderArticle__97
components_InsiderArticle__98
components_InsiderArticle__103
components_InsiderArticle__110
components_InsiderArticle__113
components_InsiderArticle__114
components_InsiderArticle__116
components_InsiderArticle__118 components_InsiderArticle__119 components_InsiderArticle__120
components_InsiderArticle__121
components_InsiderArticle__122
components_InsiderArticle__125
components_InsiderArticle__126
components_InsiderArticle__129
components_InsiderArticle__132
components_InsiderArticle__137
components_InsiderArticle__142
components_InsiderArticle__145
components_InsiderArticle__147
components_InsiderArticle__148
components_InsiderArticle__150
components_InsiderArticle__155
components_InsiderArticle__158
components_InsiderArticle__159
components_InsiderArticle__162
components_InsiderArticle__163
components_InsiderArticle__166
components_InsiderArticle__167
components_InsiderArticle__172
components_InsiderArticle__175
components_InsiderArticle__178
components_InsiderArticle__181
components_InsiderArticle__182
components_InsiderArticle__184
components_InsiderArticle__187
components_InsiderArticle__190
components_InsiderArticle__192
components_DirectorsDealingsText_5
components_InsiderArticle__196
components_InsiderArticle__197
components_InsiderArticle__199
components_InsiderArticle__200
components_InsiderArticle__203
components_InsiderArticle__206
components_InsiderArticle__209
components_InsiderArticle__212
components_InsiderArticle__215 components_DirectorsDealingsText_7 components_InsiderArticle__216 components_InsiderArticle__217